- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S9864
| Related Targets | PI3K Akt mTOR GSK-3 DNA-PK AMPK PDPK1 PTEN PP2A PDK |
|---|---|
| Other ATM/ATR Products | KU-60019 Berzosertib (VE-822) Ceralasertib (AZD6738) AZD1390 Camonsertib (RP-3500) Lartesertib (M4076) KU-55933 VE-821 AZ20 AZD0156 |
|
In vitro |
DMSO
: 17 mg/mL
(45.28 mM)
Ethanol : 3 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 375.43 | Formula | C20H21N7O |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 1876467-74-1 | -- | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | CC1COCCN1C2=CC(=C3C=CN=C(C4=CC=N[NH]4)C3=N2)C5=CC=N[N]5C | ||
| Targets/IC50/Ki |
ATR
(Cell-free assay) 7 nM
|
|---|---|
| In vitro |
Elimusertib (BAY-1895344) inhibits tumor cell growth and viability and exhibits potent antiproliferative activity in a broad spectrum of human tumor cell lines. |
| In vivo |
In cancer xenograft models with DNA damage repair deficiencies, Elimusertib (BAY-1895344) exhibits strong monotherapy efficacy. |
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05071209 | Active not recruiting | Recurrent Alveolar Rhabdomyosarcoma|Recurrent Ewing Sarcoma|Recurrent Lymphoma|Recurrent Malignant Solid Neoplasm|Refractory Alveolar Rhabdomyosarcoma|Refractory Ewing Sarcoma|Refractory Lymphoma|Refractory Malignant Solid Neoplasm |
National Cancer Institute (NCI) |
December 22 2021 | Phase 1|Phase 2 |
| NCT04267939 | Terminated | Advanced Solid Tumors (Excluding Prostate Cancer)|Ovarian Cancer |
Bayer|GlaxoSmithKline |
February 26 2020 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.